Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding.
In an open non-randomized study, 10 patients with major bleeding and an Internationalized Normal Ratio (INR) greater than 14 were treated with 5 mg of intravenous vitamin K and 30 iu/kg of a single concentrate containing factors II, VII, IX and X (Beriplex P/N; Aventis Behring). The levels of these factors before and immediately after treatment were 4.7, 1.6, 8.5 and 1.1 iu/dl and 94, 30, 66 and 91 iu/dl respectively. The median INR before treatment was greater than 20 and, after treatment, 1.1. All patients had a satisfactory clinical response with immediate cessation of bleeding, and no thromboembolic complications occurred.
Evans
G
G
Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge CB2 2QQ, UK.
Luddington
R
R
Baglin
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D015331:Cohort Studies; D004338:Drug Combinations; D005164:Factor IX / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use; D005170:Factor X / Q000627:therapeutic use; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000627:therapeutic use; D013917:Thrombin / Q000032:analysis; D014812:Vitamin K / Q000627:therapeutic use*; D014859:Warfarin / Q000009:adverse effects
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D004338:Drug Combinations; D014812:Vitamin K; D014859:Warfarin; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; D013917:Thrombin